Agios Pharmaceuticals, Inc.
) announced the initiation of a multiple ascending dose (MAD) phase
I trial on pipeline candidate AG-348.
The trial is being conducted among healthy volunteers to
characterize the safety, tolerability, pharmacokinetics and
pharmacodynamics of increasing doses of AG-348 for 14 days.
Agios is evaluating AG-348 for the treatment of pyruvate kinase
Agios initiated the trial based on encouraging data from the
ongoing single ascending dose (SAD) phase I trial wherein it was
observed that AG-348 was well tolerated to date.
Agios started the SAD trial in Apr 2014 and has completed dosing
of more than half of the planned cohorts. The company expects data
from both the studies in 2015.
We note that AG-348 is currently the only candidate in Agios'
pipeline which is being evaluated for the potential of correcting
metabolic defects found in patients with PK deficiency.
Agios, a biopharmaceutical company, focuses on the
treatment of patients suffering from cancer and inborn errors of
The lead candidates in the cancer pipeline include - AG-221 and
AG-120, which target mutant isocitrate dehydrogenase 2 and 1 while
the lead candidate in the IEM program is AG-348.
Agios has a collaboration agreement with
) with a focus on cancer metabolism. The discovery phase of the
collaboration was due to expire in Apr 2014. However, in Dec 2013,
Celgene extended the discovery phase for an additional year through
Agios Pharma currently carries a Zacks Rank #3 (Hold). Right
now, stocks like
) look attractive.
While Gilead Sciences carry a Zacks Rank #1 (Strong Buy),
Alexion Pharma is a Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research?
Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report
AGIOS PHARMACT (AGIO): Free Stock Analysis
ALEXION PHARMA (ALXN): Free Stock Analysis
GILEAD SCIENCES (GILD): Free Stock Analysis
CELGENE CORP (CELG): Free Stock Analysis Report
To read this article on Zacks.com click here.